



IFW

PATENT
Atty. Docket No.0212-CIP-9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/629,649

Inventors: Nigel R.A. BEELEY, et al.

Filed: July 30, 2003

Title: METHODS AND COMPOSITIONS FOR
TREATING POLYCYSTIC OVARY SYNDROME

Confirmation No.: 6846

TC/A.U.: 1654

Examiner: Jeffrey E. Russel

TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The following documents are enclosed herewith for your review and consideration:

- Fee Transmittal Form – In duplicate (2 pages)
- Information Disclosure Statement (2 pages)
- PTO Form SB/08 (2 pages)
- Copy of PCT International Search Report (3 pages)

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.

Dated: April 4, 2005

By: 
Mi K. Kim
Registration No. 44,830



AMYLIN PHARMACEUTICALS, INC.
9360 Town Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936


CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DC 20231

Date of Deposit

4/4/05


Name of Person Mailing Paper

Signature of Person Mailing Paper

Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).**FEE TRANSMITTAL**
For FY 2005☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$) 180.00**Complete if Known**

Application Number	10/629,649
Filing Date	July 30, 2003
First Named Inventor	Nigel R.A. BEELEY, et al.
Examiner Name	Jeffrey E. RUSSEL
Art Unit	1654
Attorney Docket No.	0212-CIP-9

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____☒ Deposit Account Deposit Account Number: 010535 Deposit Account Name: Amylin Pharmaceuticals

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	_____
Design	200	100	100	50	130	65	_____
Plant	200	100	300	150	160	80	_____
Reissue	300	150	500	250	600	300	_____
Provisional	200	100	0	0	0	0	_____

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims
_____ - 20 or HP = _____	x _____	= _____		Fee (\$) Fee Paid (\$)

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
_____ - 3 or HP = _____	x _____	= _____	

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
_____ - 100 = _____	/ 50 = _____	(round up to a whole number) x _____	= _____	

4. OTHER FEE(S)


Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Submission of an Information Disclosure Statement **Fees Paid (\$)** \$180.00**SUBMITTED BY**

Signature		Registration No. (Attorney/Agent) 44,830	Telephone 858-552-2200
Name (Print/Type)	Mi K. Kim	Date April 4, 2005	

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT
Serial No. 10/629,649
Amylin Docket No.: 0212-CIP-9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

AMYLIN PHARMACEUTICALS, INC.

Applicants: Nigel R.A. BEELEY, et al

Serial No.: 10/629,649

Filed: July 30, 2003

Title: METHODS AND COMPOSITIONS
FOR TREATING POLYCYSTIC
OVARY SYNDROME

Group Art Unit: 1654

Examiner: Jeffrey E. Russel

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. §1.97(c), the articles and patent documents listed and identified on the attached Form PTO/SB/08 are being submitted before the mailing of a final action under 1.113, a notice of allowance under 1.311, or an action that otherwise closes prosecution in the application and is accompanied by the fee set forth in 1.17(p).

Attached are Forms PTO/SB/08a and 08b (formerly Form PTO-1449). Copies of the listed references are enclosed. The Examiner is requested to consider the references and make them of record.

CERTIFICATE OF MAILING
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

4/4/05

Deborah Wykes

Name of Person Mailing Paper

Signature of Person Mailing Paper

04/06/2005 EAREGAY1 00000030 010535 10629649

01 FC:1806 180.00 DA


Applicants submit that the filing of the information disclosure statement should not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56(b). Also enclosed is a copy of the PCT International Search Report.

A fee of \$180.00 is believed due in connection with this communication. The Commissioner is hereby authorized to charge payment of this and any additional fees associated with this communication or credit any overpayment to Amylin Pharmaceuticals, Inc.'s Deposit Account No. 010535.


Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: 4/4/2005

By: 
Mi K. Kim
Registration No. 44,830

AMYLIN PHARMACEUTICAL, INC.
9360 Town Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936




Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet	1	of	2
-------	---	----	---

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

<i>Application Number</i>	10/629,649
<i>Filing Date</i>	July 30, 2003
<i>First Named Inventor</i>	Nigel R.A. BEELEY, et al
<i>Art Unit</i>	1646
<i>Examiner Name</i>	Jeffrey E. Russel
<i>Attorney Docket Number</i>	0212-CIP-9

Sheet	2	of	2
-------	---	----	---

[illegible]Date
Considered

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.